Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark.
Thyroid. 2012 Sep;22(9):918-25. doi: 10.1089/thy.2012.0005. Epub 2012 Jul 24.
The expanding use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) has led to the identification of increasing numbers of patients with an incidentaloma in the thyroid gland. We aimed to review the proportion of incidental thyroid cancers found by (18)F-FDG PET or PET/computed tomography imaging.
Studies evaluating thyroid carcinomas discovered incidentally in patients or healthy volunteers by (18)F-FDG PET were systematically searched in the PubMed database from 2000 to 2011. The main exclusion criteria were known thyroid disease, lack of assigned diagnoses, investigation of diffuse uptake only, or investigation of patients with head and neck cancer, or cancer in the upper part of the thorax.
Twenty-two studies met our criteria comprising a total of 125,754 subjects. Of these, 1994 (1.6%) had unexpected focal hypermetabolic activity, while 999 of 48,644 individuals (2.1%) had an unexpected diffuse hypermetabolic activity in the thyroid gland. A diagnosis was assigned in 1051 of the 1994 patients with a focal uptake, 366 of whom (34.8%) had thyroid malignancy. Likewise, a diagnosis was assigned in 168 of 999 patients with a diffuse uptake, 7 of whom (4.4%) had thyroid malignancy. In the eight studies reporting individual maximum standardized uptake values (SUV(max)), the mean SUV(max) was 4.8 (standard deviation [SD] 3.1) and 6.9 (SD 4.7) in benign and malignant lesions, respectively (p<0.001).
Incidentally found thyroid nodules, using (18)F-FDG PET, are at high risk of harboring malignancy if uptake is focal. SUV are significantly higher in malignant than in benign nodules. The pronounced inhomogeneity and other shortcomings of the studies are discussed.
正电子发射断层扫描术(PET)应用的日益广泛导致偶然发现甲状腺 INCIDENTALOMA 的患者数量不断增加。我们旨在回顾(18)F-氟代脱氧葡萄糖正电子发射断层扫描(18)F-FDG PET 或 PET/计算机断层扫描成像偶然发现的甲状腺癌的比例。
从 2000 年至 2011 年,我们在 PubMed 数据库中系统地搜索了评估(18)F-FDG PET 偶然发现的甲状腺癌的患者或健康志愿者的研究。主要排除标准是已知的甲状腺疾病、缺乏指定诊断、仅调查弥漫性摄取或调查头颈部癌症或胸部上部癌症的患者。
22 项研究符合我们的标准,共纳入 125754 例患者。其中 1994 例(1.6%)出现意外局灶性高代谢活性,而 48644 例中有 999 例(2.1%)出现甲状腺弥漫性高代谢活性。在 1994 例局灶性摄取的患者中,有 1051 例诊断,其中 366 例(34.8%)为甲状腺恶性肿瘤。同样,在 999 例弥漫性摄取的患者中,有 168 例诊断,其中 7 例(4.4%)为甲状腺恶性肿瘤。在报告个体最大标准化摄取值(SUV(max))的 8 项研究中,良性和恶性病变的平均 SUV(max)分别为 4.8(标准差[SD]3.1)和 6.9(SD4.7)(p<0.001)。
如果摄取是局灶性的,(18)F-FDG PET 偶然发现的甲状腺结节恶性肿瘤的风险很高。恶性结节的 SUV 明显高于良性结节。讨论了研究中明显的异质性和其他缺点。